



Republic of the Philippines

DEPARTMENT OF SCIENCE AND TECHNOLOGY



MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF)

As of 07 March 2023, the Health Technology Assessment Council (HTA Council) has completed the assessment and deliberation for the preliminary recommendation on **dapagliflozin 10 mg single-dose film-coated tablets** as add-on treatment for adults with Type 2 Diabetes Mellitus including those who have or are at high risk of cardiovascular disease and/or diabetic nephropathy.

The HTA Council hereby makes public its **preliminary recommendation for the government financing of *Dapagliflozin 10 mg acid single-dose film-coated tablets* through its inclusion in the Philippine National Formulary (PNF).**

Supporting studies that informed the recommendation of HTA Council can be found in the evidence summary accessible through this link: <https://bit.ly/ESDapaglifloznT2DM>. All comments, inputs, and/or appeals may be submitted until **21 March 2023**, for the consideration of the HTAC, through email at hta@doh.gov.ph.

Please use the prescribed form for appeals indicated in the HTA Philippines website [hta.doh.gov.ph/topic-nomination/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please do not hesitate to contact us *via email* at hta@doh.gov.ph or *via telephone call* via 88757734 loc 260.

Thank you very much and best regards.

ANNE JULIENNE BENUINO-MARFORI, RPh, MSc

Division Chief

Health Technology Assessment Division

Health Regulation Team

Postal Address: DOST Complex, General Santos Avenue
Bicutan, Taguig City 1631
P.O. Box 3596 Manila

Tel. Nos.: Trunkline (+632) 8837-2071 to 82; 8837-3171 to 89

Fax No. : OSEC (+632) 8837-2937; Records (+632) 8837-7493

Website : www.dost.gov.ph